This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, Y. S.
Right arrow Articles by Cooper, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, Y. S.
Right arrow Articles by Cooper, S. W.

PEDIATRICS Vol. 100 No. 6 December 1997, pp. 1042

Revised Group B Streptococcal (GBS) Infection Guidelines

The first 20% of the full text of this article appears below.

To the Editor.

The new 1997 guidelines for the management of group B streptococcal (GBS) infections in newborns have been recently published.1,2 The major change we wish to address is the use of intrapartum chemoprophylaxis in GBS carriers identified by anogenital cultures.

The 1992 guidelines recommended intrapartum chemoprophylaxis only if risk factors were present (preterm rupture, preterm labor, fever during labor, multiple births, and rupture of membranes >18 hours).3 The current recommendation is to offer intrapartum chemoprophylaxis to all GBS carriers regardless of risk factors. We agree and offer our ongoing experience with this new strategy.

Our institution experienced an outbreak of invasive neonatal GBS over a . . . [Full Text of this Article]